218 related articles for article (PubMed ID: 12529935)
1. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.
Brubaker PL; Drucker DJ
Recept Channels; 2002; 8(3-4):179-88. PubMed ID: 12529935
[TBL] [Abstract][Full Text] [Related]
2. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
[TBL] [Abstract][Full Text] [Related]
3. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
[TBL] [Abstract][Full Text] [Related]
4. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
Wang JH; Inoue T; Higashiyama M; Guth PH; Engel E; Kaunitz JD; Akiba Y
J Pharmacol Exp Ther; 2011 Nov; 339(2):464-73. PubMed ID: 21846840
[TBL] [Abstract][Full Text] [Related]
5. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors.
Preitner F; Ibberson M; Franklin I; Binnert C; Pende M; Gjinovci A; Hansotia T; Drucker DJ; Wollheim C; Burcelin R; Thorens B
J Clin Invest; 2004 Feb; 113(4):635-45. PubMed ID: 14966573
[TBL] [Abstract][Full Text] [Related]
6. Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells.
Gallwitz B; Witt M; Fölsch UR; Creutzfeldt W; Schmidt WE
J Mol Endocrinol; 1993 Jun; 10(3):259-68. PubMed ID: 8396943
[TBL] [Abstract][Full Text] [Related]
7. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
[TBL] [Abstract][Full Text] [Related]
9. The incretins: a link between nutrients and well-being.
Burcelin R
Br J Nutr; 2005 Apr; 93 Suppl 1():S147-56. PubMed ID: 15877888
[TBL] [Abstract][Full Text] [Related]
10. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
11. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
[TBL] [Abstract][Full Text] [Related]
12. Typical Danish Caucasian type 2 diabetic patients do not commonly carry genetic variants in GIP and GLP-1 encoding regions of the proGIP and proglucagon genes.
Ørskov C; Hjorth SA; Jensen AD; Vilsbøll T
Regul Pept; 2004 Jul; 119(3):151-4. PubMed ID: 15120474
[TBL] [Abstract][Full Text] [Related]
13. Evolutionarily conserved residues at glucagon-like peptide-1 (GLP-1) receptor core confer ligand-induced receptor activation.
Moon MJ; Kim HY; Park S; Kim DK; Cho EB; Park CR; You DJ; Hwang JI; Kim K; Choe H; Seong JY
J Biol Chem; 2012 Feb; 287(6):3873-84. PubMed ID: 22105074
[TBL] [Abstract][Full Text] [Related]
14. Biology of incretins: GLP-1 and GIP.
Baggio LL; Drucker DJ
Gastroenterology; 2007 May; 132(6):2131-57. PubMed ID: 17498508
[TBL] [Abstract][Full Text] [Related]
15. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
Gallwitz B; Witt M; Morys-Wortmann C; Fölsch UR; Schmidt WE
Regul Pept; 1996 May; 63(1):17-22. PubMed ID: 8795084
[TBL] [Abstract][Full Text] [Related]
16. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
Holst JJ
BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
[TBL] [Abstract][Full Text] [Related]
17. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of human incretin receptor missense variants.
Fortin JP; Schroeder JC; Zhu Y; Beinborn M; Kopin AS
J Pharmacol Exp Ther; 2010 Jan; 332(1):274-80. PubMed ID: 19841474
[TBL] [Abstract][Full Text] [Related]
19. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 and control of insulin secretion.
Thorens B
Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
